Business & Economy · 40 views
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
Business & Economy 
Story intelligence
Coverage Single outlet Single-outlet story
Views 40 Community interest
Brief read Under 1 min brief 39 words
Summary
Jason V. Coloma, Chief Executive Officer of Maze Therapeutics (NASDAQ:MAZE), reported the indirect sale of 27,858 shares of common stock over three open-market transactions on June 22 and June 23, 2026, according to the SEC Form 4 filing .
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- Ian Buck built Nvidia's secret weapon. Jensen Huang's departure makes it even more essential to the company's future.Continue reading
- Anthropic’s blockbuster IPO just got harder after Jensen Huang’s dramatic exit as Nvidia CEOContinue reading
- The scandal at Nvidia is exactly what’s wrong with the S&P 500Continue reading
- Buy Nvidia with 'both hands' because the valuation is at 'stupid' levels, says analyst MeeksContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow